Azithromycin suspension pediatric dosage for azithromycin


Contraindications

Documented hypersensitivity; hyperbilirubinemic neonates, particularly those who are premature; neonates <28 days if they receive calcium-containing IV products

Intravenous administration of ceftriaxone solutions containing lidocaine

Lidocaine contraindications if lidocaine solution used as solvent with ceftriaxone for intramuscular injection

Concomitant calcium-ceftriaxone azithromycin suspension pediatric dosage for azithromycin administration

  • Risk of fatal calcium-ceftriaxone precipitant formation in lungs and kidneys of term and preterm neonates
  • <28 days: Do not give any calcium-containing IV drugs or products within 48 hours of ceftriaxone (within 5 days if neonate is <10 days, per Health Canada)
  • >28 days: Calcium may be given in sequence after ceftriaxone once infusion line has been flushed, but not simultaneously in same bag or line (chemically incompatible)

Cautions

10-g pharmacy bulk package should not be used for direct infusion

Immune-mediated hemolytic anemia reported; if patient develops anemia while on ceftriaxone, stop antibiotic until etiology determined; severe hemolytic anemia, including fatalities, reported in both adults and children

May increase INR, especially in nutritionally deficient patients, hepatic or renal disease or prolonged treatment

Dosage must be adjusted in severe renal insufficiency (high dosages may cause CNS toxicity)

Superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy

Use with caution in patients with history of penicillin allergy

Use with caution in patients with history of GI disease, especially colitis

Use with caution in breast-feeding women; drug may displace bilirubin from albumin-binding sites, increasing risk of kernicterus

Abnormal gallbladder sonograms reported, possibly the result of ceftriaxone-calcium precipitates; discontinue if signs or symptoms of gallbladder diseease occur

Ceftriaxone-calcium precipitates in urinary tract observed in patients receiving ceftriaxone; may be detected as sonographic abnormalities; patients may be asymptomatic or may develop symptoms of urolithiasis, and ureteral obstruction and post-renal acute renal failure; appears to be reversible upon discontinuation of therapy and institution of appropriate management; ensure adequate hydration; discontinue therapy in patients who develop signs and symptoms suggestive of urolithiasis, oliguria or renal failure and/or the sonographic findings

Clostridium difficile-associated diarrhea (CDAD reported with use of nearly all antibacterial agents, including ceftriaxone; If CDAD suspected or confirmed, may consider discontinuing ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation

Pancreatitis secondary to biliary obstruction reported rarely; use with caution in patients with gallbladder, biliary tract, liver, or pancreatic disease and patients with history of penicillin hypersensitivity

Use with caution in patients with history of GI disease (eg, colitis)


Source: http://reference.medscape.com/drug/rocephin-ceftriaxone-342510


///

Zithromax 250 mg and 500 mg Tablets and Oral Suspension Azithromycin lexicomp


Azithromycin suspension pediatric dosage for azithromycin Orally Disintegrating Films and Mini. - SpringerLink
Azithromycin suspension pediatric dosage for azithromycin Zithromax (Azithromycin Side Effects, Interactions)
Azithromycin suspension pediatric dosage for azithromycin AZITHROMYCIN - azithromycin powder, for suspension
Azithromycin suspension pediatric dosage for azithromycin Azithromycin Dosage Guide with Precautions - m
Azithromycin suspension pediatric dosage for azithromycin AZITHROMYCIN DIHYDRATE C38H76N2O14 - PubChem
Azithromycin suspension pediatric dosage for azithromycin Zithromax Dosage Guide - m

///
Дата: 31.08.2017, 03:46 / Просмотров: 83365